Vir Biotechnology Inc. (VIR) and GlaxoSmithKline's (GSK) Sotrovimab Retains Activity Against Key Omicron Mutations, per Preclinical Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oil surges 5%, Brent and US crude both over $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Pre-Open Stock Movers 11/30: (CPIX) (IMGN) (VIR) Higher; (JKS) (LIZI) (SEDG) Lower (more...)
November 30, 2021 9:28 AM ESTPre-Open Movers
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) 129% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The non-narcotic pain reliever may now be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.
ImmunoGen Inc. (Nasdaq: IMGN) 45.5% HIGHER; announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy... More
Vir Biotechnology (VIR) PT Raised to $200 at H.C. Wainwright
November 30, 2021 9:17 AM ESTH.C. Wainwright analyst Patrick Trucchio raised the price target on Vir Biotechnology (NASDAQ: VIR) to $200.00 (from $135.00) while maintaining a Buy rating.
The analyst commented, "Several recent updates suggest to us that Vir and its collaboration partner GlaxoSmithKline (GSK; not rated) are likely to maintain a top-tier COVID-19 antiviral franchise, led at first by sotrovimab, an FDA EUA-authorized investigational single-dose intravenous (IV) infusion SARS-CoV-2 monoclonal antibody (mAb), for the foreseeable future including: (1) on November 26, the... More
